AACR-2016 Clinical Trial Post #3: AM0010
Clinical trial abstracts of the AACR meeting next week were released this afternoon. AACR presents some clinical trial results - the ASCO conference in June presents much more. A lot of eyes will be on the PD1/Avastin/FOLFOX trial results which will be presented on Monday to see if they mention MSS-CRC. Once I hear feedback what was said, I'll post next week on that one.
Today I'll post (3) clinical trial poster abstracts I noticed with CRC data and with currently open trials.
Title: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors
Open Trial: https://clinicaltrials.gov/ct2/show/NCT ... 010&rank=1
CRC Data: “Prolonged stable disease of 6 or more months was observed in several indications including colon cancer” (doesn’t say if MSS or MSI-high or % of CRC patients showing stable disease)
Side effects: See abstract for details, not being dosed at MTD
Full abstract: http://www.abstractsonline.com/plan/Vie ... 0fb1922267
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List